{"title": "Risk for Transportation of 2019 Novel Coronavirus (COVID-19) from Wuhan to Cities in China", "doi": "10.1101/2020.01.28.20019299", "citation_id": "2020.01.28.20019299v4", "date": "2020-02-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.01.28.20019299", "abstract": "<p>On January 23, 2020, China quarantined Wuhan to contain an emerging coronavirus (COVID-19). We estimated the probability of transportation of COVID-19 from Wuhan to 369 cities in China before the quarantine. The expected risk is &gt;50% in 130 (95% CI 89-190) cities and &gt;99% in the 4 largest metropolitan areas of China.</p>", "twitter_description": "On January 23, 2020, China quarantined Wuhan to contain an emerging coronavirus (COVID-19). We estimated the probability of transportation of COVID-19 from Wuhan to 369 cities in China before the quarantine. The expected risk is >50% in 130 (95% CI 89-190) cities and >99% in the 4 largest metropolitan areas of China.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nWe acknowledge the financial support from NIH (U01 GM087719), the Investissement d\u0092Avenir program, the Laboratoire d\u0092Excellence Integrative Biology of Emerging Infectious Diseases program (Grant ANR-10-LABX-62-IBEID) and European Union V.E.O project. None of the authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nData will become available upon publication in a peer-reviewed journal.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.01.28.20019299v4.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.01.28.20019299v4", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.01.28.20019299v4.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.01.28.20019299.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.01.28.20019299v4", "access_rights": "restricted", "authors": ["Zhanwei Du", "Ling Wang", "Simon Cauchemez", "Xiaoke Xu", "Xianwen Wang", "Benjamin J Cowling", "Lauren Ancel Meyers"]}